Pharmathen
- Company typePrivate
- Founded1969
- HeadquartersAmstelveen, Netherlands
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Pharmathen firmographics
Firmographics- Name
- Pharmathen
- Website
- https://pharmathen.com
- Company type
- Private
- Founded year
- 1969
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Pharmathen industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Pharmathen is headquartered
LocationHeadquarters
- HQ city
- Amstelveen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Pharmathen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Contract Manufacturing Services: Provides contract development and manufacturing services for pharmaceutical products, including injectable drugs, serving as an exclusive manufacturer for products like Lanreotide for Cipla
Distribution channels1 record
Pharmathen product offering
Product offeringCore offering
Pharmathen is a Greek-headquartered pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). It specializes in advanced drug delivery, particularly the development and manufacturing of complex injectable pharmaceutical products and active pharmaceutical ingredients for global pharmaceutical partners.
Product overview
Pharmathen is a Greek pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO) specializing in advanced drug delivery solutions. Based on the available sources, Pharmathen manufactures injectable pharmaceutical products, including Lanreotide (a somatostatin analog used for treating acromegaly and neuroendocrine tumors), at their Rodopi facility in Greece. The company is positioned within the global advanced drug delivery CDMO market alongside competitors such as Evonik Health Care, SHL Medical, and Lubrizol Life Science. Pharmathen serves as a manufacturing partner for pharmaceutical companies including Cipla, supplying products exclusively for the US market. The company's capabilities include manufacturing of sterile injectable drug products with regulatory compliance for global markets including US FDA requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- Lanreotide Injection
- Advanced Drug Delivery Systems
- Injectable Pharmaceutical Manufacturing Services
- Active Pharmaceutical Ingredient (API) Manufacturing
Companies that use Pharmathen
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Pharmathen technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pharmathen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CiplacorePharmathen is the exclusive manufacturer of Lanreotide Injection for Cipla USA Inc. The Rodopi facility in Greece is the sole supplier of this key product, which is among Cipla's top three US products. The partnership has been disrupted due to FDA compliance issues at the facility.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
Pharmathen competitors and assessment
Company assessmentBroad incumbents
- Catalent: Large global CDMO with significant sterile injectable and biologics fill-finish operations. A broad incumbent that competes with Pharmathen for injectable pharmaceutical contracts but operates at significantly greater scale across multiple dosage forms and modalities.
- Patheon (Thermo Fisher Scientific): Part of Thermo Fisher's pharma services segment, offering contract development and manufacturing including sterile injectables. A broad incumbent with substantially larger scale that competes with Pharmathen in injectable CDMO services.
Direct peers
- Fareva: French-headquartered CDMO operating sterile injectable manufacturing facilities in Europe, including for advanced drug delivery formats. Directly comparable contract manufacturing services to Pharmathen's injectable CDMO offerings.
- Corden Pharma: Peptide and injectable CDMO with integrated API-to-drug-product capabilities. Comparable to Pharmathen given peptide injectable manufacturing (Lanreotide) and integrated development services for complex parenteral products.
- Aenova Group: European CDMO with strong sterile injectable and aseptic fill-finish capabilities serving pharmaceutical companies globally. Comparable to Pharmathen's injectable manufacturing and advanced drug delivery focus.
- Recipharm: Swedish-headquartered CDMO with significant sterile injectable manufacturing capabilities and a generic-pharma customer base. Directly comparable business model to Pharmathen as a parenteral-focused CDMO serving branded and generic pharma.
- SHL Medical: Named alongside Pharmathen in the advanced drug delivery CDMO market. SHL Medical specializes in injectable drug delivery systems and auto-injector device manufacturing, directly overlapping with Pharmathen's injectable CDMO positioning.
- Evonik Health Care: Explicitly listed alongside Pharmathen as a major player in the global advanced drug delivery CDMO market. Evonik Health Care offers comparable parenteral drug delivery and CDMO services, directly competing for injectable pharmaceutical contracts.
- Lubrizol Life Science: Listed as a peer in the advanced drug delivery CDMO space. Lubrizol Life Science provides contract development and manufacturing for complex drug delivery formats including parenterals, making it a directly comparable CDMO peer.
- Acino International AG: Co-listed with Pharmathen among global advanced drug delivery CDMOs. Acino offers contract manufacturing for modified-release and specialty pharmaceutical products, including injectables, directly comparable to Pharmathen's service offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Pharmathen social profiles
Digital presencePharmathen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmathen leadership team
Management profileNumber of profiles
Profiles2 records
Pharmathen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmathen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmathen
What does Pharmathen do?
Pharmathen is a Greek-headquartered pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). It specializes in advanced drug delivery, particularly the development and manufacturing of complex injectable pharmaceutical products and active pharmaceutical ingredients for global pharmaceutical partners.
Is Pharmathen a public or private company?
Pharmathen is a private company. It is classified as unknown and is currently operating.
When was Pharmathen founded?
Pharmathen was founded in 1969. It employs 501 to 1,000 people.
Where is Pharmathen based?
Pharmathen is headquartered in Amstelveen, Netherlands, in the Europe region.
How does Pharmathen make money?
One revenue line is on record: contract Manufacturing Services.
Who are Pharmathen's main competitors?
Broad incumbents on record are Catalent and Patheon (Thermo Fisher Scientific). Direct peers are Fareva, Corden Pharma, Aenova Group, Recipharm, SHL Medical, Evonik Health Care, Lubrizol Life Science and Acino International AG.
Does Pharmathen have an API?
No public API is recorded for Pharmathen.
What industry is Pharmathen in?
Pharmathen's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.